BTG plc (LON:BTG)‘s stock had its “buy” rating reissued by analysts at Numis Securities Ltd in a note issued to investors on Wednesday, October 18th. They currently have a GBX 900 ($11.84) price target on the stock. Numis Securities Ltd’s target price indicates a potential upside of 21.87% from the company’s current price.
BTG has been the subject of several other reports. J P Morgan Chase & Co restated a “neutral” rating on shares of BTG plc in a research note on Friday, October 6th. Peel Hunt reaffirmed a “hold” rating and set a GBX 680 ($8.94) target price on shares of BTG plc in a research note on Wednesday, September 20th. Deutsche Bank AG reiterated a “buy” rating and set a GBX 775 ($10.19) price target on shares of BTG plc in a research note on Friday, October 13th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 800 ($10.52) price target on shares of BTG plc in a research note on Wednesday, August 30th. Finally, Shore Capital reiterated a “not rated” rating on shares of BTG plc in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. BTG plc currently has a consensus rating of “Buy” and an average price target of GBX 779.13 ($10.25).
Shares of BTG plc (LON BTG) traded down GBX 40.50 ($0.53) on Wednesday, reaching GBX 738.50 ($9.71). 1,324,734 shares of the company’s stock traded hands, compared to its average volume of 537,528. BTG plc has a 52 week low of GBX 528.36 ($6.95) and a 52 week high of GBX 779 ($10.25).
TRADEMARK VIOLATION WARNING: This report was reported by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://baseballnewssource.com/markets/btg-plc-btg-earns-buy-rating-from-numis-securities-ltd/1723127.html.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with our FREE daily email newsletter.